Research programme: skin cancer therapeutics - LEO Pharma/University of Queensland
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator LEO Pharma; University of Queensland
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Skin-cancer in Australia
- 04 Nov 2017 No recent reports of development identified for research development in Skin-cancer in Denmark
- 08 Oct 2013 Early research in Skin cancer in Australia and Denmark (unspecified route)